Barriers and Facilitators in Diagnostic Pathways That Align Universal Tumor Screening and Mainstream Genetic Testing for Lynch Syndrome in Colorectal Cancer: Protocol fora Scoping Review With a Narrative Synthesis

被引:0
作者
Battistuzzi, Linda [1 ]
Blondeaux, Eva [2 ]
Puccini, Alberto [3 ,4 ]
Boni, Luca [2 ]
Grillo, Federica [5 ,6 ]
Trevisan, Lucia [7 ]
Varesco, Liliana [7 ]
Sciallero, Maria Stefania [8 ]
机构
[1] IRCCS Osped Policlin San Martino, Med Oncol Unit 2, Largo Rosanna Benzi 10, I-16132 Genoa, Italy
[2] IRCCS Osped Policlin San Martino, Clin Epidemiol Unit, Genoa, Italy
[3] Humanitas Univ, Dept Biomed Sci, Milan, Italy
[4] IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Med Oncol & Hematol Unit, Milan, Italy
[5] IRCCS Osped Policlin San Martino, Anat Pathol Unit, Genoa, Italy
[6] Univ Genoa, Dept Surg & Integrated Diagnost Sci, Genoa, Italy
[7] IRCCS Osped Policlin San Martino, Hereditary Canc Unit, Genoa, Italy
[8] IRCCS Osped Policlin San Martino, Med Oncol Unit 1, Genoa, Italy
关键词
Scoping review; protocol; colorectal cancer; Lynch syndrome; diagnostic pathway; genetic testing; mainstreaming; barriers; facilitators; implementation; theoretical domains framework; GUIDELINES; SOCIETY;
D O I
10.2196/70831
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Approximately 3% of colorectal cancers (CRCs) are dueto Lynch syndrome (LS), a hereditary cancer syndrome caused by pathogenic variants (PVs) in the mismatch repair (MMR) genes. Patients with CRC and LS have elevated lifetime risks for a range of cancers and require personalized treatment and targeted surveillance. Relatives of people affected by LS who share the same PV also have elevated cancer risks and can benefit from preventive measures and/or risk-reducing surgeries. Despite this, LS remains vastly underdiagnosed. Universal tumor screening (UTS) for deficient MMR is recommended in diagnosing LS in patients with CRC. This process, when combined with genetic testing (GT) offered within routine cancer care (termed "mainstream GT"), aims to identify individuals at risk efficiently, but integrating UTS and mainstream GT for LS in CRC is a complex endeavor. Objective: The aim of the proposed scoping review will be to comprehensively explore the literature on diagnostic pathways comprising UTS and mainstream GT for LS among patients with CRC and barriers and facilitators in their implementation. Methods: The scoping review will follow Arksey and O'Malley's expanded framework. Results will be reported following the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) guidelines and summarized quantitatively. A narrative synthesis will also be performed using the Theoretical Domains Framework. Results: The results will be presented in a forthcoming scoping review, which we expect to publish in a peer-reviewed journal by early 2026. Conclusions:Aligning UTS with mainstream GT for LS in CRC may boost early diagnosis and prevention while reducing waiting times and other patient burdens. By addressing barriers to and facilitators in diagnostic pathways, health care systems can improve the identification and management of LS, ultimately leading to better outcomes for patients and their families. The insights gained from this scoping review will inform the development of a mixed methods study about implementing diagnostic pathways for LS in CRC that integrate UTS and mainstream GT in Italy.
引用
收藏
页数:7
相关论文
共 40 条
[1]  
Arksey H., 2005, Int J Soc Res Methodol, V8, P19, DOI [10.1080/1364557032000119616, DOI 10.1080/1364557032000119616, DOI 10.1080/136455]
[2]  
Battistuzzi L, 2021, NEW ENGL J MED, V384, P971, DOI 10.1056/NEJMc2036233
[3]  
Berg AO, 2009, GENET MED, V11, P35, DOI [10.1097/GIM.0b013e318181fa2ff, 10.1097/GIM.0b013e31818fa2ff]
[4]   The Feasibility of Implementing Mainstream Germline Genetic Testing in Routine Cancer Care-A Systematic Review [J].
Bokkers, Kyra ;
Vlaming, Michiel ;
Engelhardt, Ellen G. ;
Zweemer, Ronald P. ;
van Oort, Inge M. ;
Kiemeney, Lambertus A. L. M. ;
Bleiker, Eveline M. A. ;
Ausems, Margreet G. E. M. .
CANCERS, 2022, 14 (04)
[5]   Universal molecular screening does not effectively detect Lynch syndrome in clinical practice [J].
Brennan, Beatrice ;
Hemmings, Christine T. ;
Clark, Ian ;
Yip, Desmond ;
Fadia, Mitali ;
Taupin, Douglas R. .
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2017, 10 (04) :361-371
[6]  
Burn John, 2023, BMJ Oncol, V2, pe000211, DOI 10.1136/bmjonc-2023-000211
[7]   Validation of the theoretical domains framework for use in behaviour change and implementation research [J].
Cane, James ;
O'Connor, Denise ;
Michie, Susan .
IMPLEMENTATION SCIENCE, 2012, 7
[8]   MLH1 Promoter Methylation Could Be the Second Hit in Lynch Syndrome Carcinogenesis [J].
Carnevali, Ileana Wanda ;
Cini, Giulia ;
Libera, Laura ;
Sahnane, Nora ;
Facchi, Sofia ;
Viel, Alessandra ;
Sessa, Fausto ;
Tibiletti, Maria Grazia .
GENES, 2023, 14 (11)
[9]   Scoping reviews: time for clarity in definition, methods, and reporting [J].
Colquhoun, Heather L. ;
Levac, Danielle ;
O'Brien, Kelly K. ;
Straus, Sharon ;
Tricco, Andrea C. ;
Perrier, Laure ;
Kastner, Monika ;
Moher, David .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2014, 67 (12) :1291-1294
[10]  
Diagnostics Assessment Programme, 2017, Molecular testing for Lynch syndrome in people with colorectal cancer